Close
Nordic 9Nordic 9

Pontifax Venture Capital (investor - Venture Capital)

Israel pontifax.com
See something wrong or missing? Let us know
Offices:Tel Aviv
Average round investment:66.74M USD
Average number per year:2.3
Distribution: 2024 (4)2023 (2)2022 (1)2021 (4)2020 (2) See the entire list
Portfolio companies: Denmark AdcendoBelgium AgomabNetherlands Adcytherix See the entire list
Mostly invests in: Denmark Denmark (3) Health services (13)
See the entire list

Showing 3 of 14 tracked investments in:

You need an account to access this feature. Log in or create one from here.

Do you have a question? Talk to us.

Pontifax Venture Capital mostly invests with:

You need an account to access this feature. Log in or create one from here.

Do you have a question? Talk to us.

Investors with similar profile to Pontifax Venture Capital

Name Criteria
France Lauxera Capital Partners
83%
  • Range for average deal size: 50M - 100M USD
  • Similar verticals: Health services, Biotech, Manufacturing, Pharma
  • Similar business models: B2B
  • Common investees countries: France, Denmark, Germany, United Kingdom
  • Average number of deals per year: 2.0
  • Active last 12 months: Yes
United States Northpond Ventures
83%
  • Range for average deal size: 50M - 100M USD
  • Similar verticals: Health services, Biotech, Manufacturing, Pharma
  • Similar business models: B2B
  • Common investees countries: Switzerland, Germany, United Kingdom
  • Average number of deals per year: 2.0
  • Active last 12 months: Yes
United Kingdom Dawn Biopharma
83%
  • Range for average deal size: 50M - 100M USD
  • Similar verticals: Health services, Biotech, Manufacturing, Pharma
  • Similar business models: B2B
  • Common investees countries: Belgium, Netherlands, Denmark
  • Average number of deals per year: 2.0
  • Active last 12 months: Yes
United States Bristol-Myers Squibb
83%
  • Range for average deal size: 50M - 100M USD
  • Similar verticals: Health services, Biotech, Manufacturing, Pharma
  • Similar business models: B2B
  • Common investees countries: France, Denmark, Germany, United Kingdom
  • Average number of deals per year: 1.8
  • Active last 12 months: Yes
United States Omega Funds
83%
  • Range for average deal size: 50M - 100M USD
  • Similar verticals: Health services, Biotech, Manufacturing, Pharma
  • Similar business models: B2B
  • Common investees countries: Belgium, Switzerland, Germany, United Kingdom
  • Average number of deals per year: 1.8
  • Active last 12 months: Yes
United States Versant Ventures
83%
  • Range for average deal size: 50M - 100M USD
  • Similar verticals: Health services, Biotech, Manufacturing, Pharma
  • Similar business models: B2B
  • Common investees countries: Switzerland, United Kingdom
  • Average number of deals per year: 1.5
  • Active last 12 months: Yes
Singapore ABC World
83%
  • Range for average deal size: 50M - 100M USD
  • Similar verticals: Health services, Biotech, Manufacturing
  • Similar business models: B2B
  • Common investees countries: France, United Kingdom
  • Average number of deals per year: 1.5
  • Active last 12 months: Yes
France ISALT
83%
  • Range for average deal size: 50M - 100M USD
  • Similar verticals: Health services, Manufacturing, Agriculture
  • Similar business models: B2B
  • Common investees countries: France
  • Average number of deals per year: 1.5
  • Active last 12 months: Yes
United States Arch Venture Partners
83%
  • Range for average deal size: 50M - 100M USD
  • Similar verticals: Health services, Biotech, Manufacturing
  • Similar business models: B2B
  • Common investees countries: Germany, United Kingdom
  • Average number of deals per year: 1.4
  • Active last 12 months: Yes
United States Deerfield Management
83%
  • Range for average deal size: 50M - 100M USD
  • Similar verticals: Health services, Biotech, Manufacturing, Pharma
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 1.3
  • Active last 12 months: Yes
Top